Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

Details

Serval ID
serval:BIB_605A7A84D42A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
Journal
European Journal of Cancer
Author(s)
Woll  P. J., Judson  I., Lee  S. M., Rodenhuis  S., Nielsen  O. S., Buesa  J. M., Lorigan  P. C., Leyvraz  S., Hermans  C., van Glabbeke  M., Verweij  J.
ISSN
0959-8049 (Print)
Publication state
Published
Issued date
03/1999
Volume
35
Number
3
Pages
410-2
Notes
Clinical Trial
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Mar
Abstract
Temozolomide, an oral imidazotetrazine derivative, was given to 31 patients with advanced soft tissue sarcoma. The dose of 750 mg/m2 was divided over 5 consecutive days, and escalated to 1000 mg/m2 over 5 days at cycle 2 if myelosuppression no worse than common toxicity criteria grade 2 was noted in the first 28-day cycle. A total of 99 treatment cycles were given to 31 patients. The drug was well tolerated, with nausea and vomiting as the most common side-effects. Only one partial tumour response was documented, giving a response rate of 3.33%, 95% confidence interval, (CI) 0.1-17.2%. The median time to progression was 8 weeks and the median survival was 27 weeks. These results indicate that temozolomide in this schedule is not active as second-line treatment in advanced soft tissue sarcoma.
Keywords
Adult Aged Antineoplastic Agents, Alkylating/adverse effects/*therapeutic use Dacarbazine/adverse effects/*analogs & derivatives/therapeutic use Female Humans Male Middle Aged Sarcoma/*drug therapy Survival Analysis Treatment Outcome
Pubmed
Web of science
Create date
28/01/2008 8:32
Last modification date
20/08/2019 14:17
Usage data